Finance News
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Also Received an $11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression
A Landmark October 30th FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) at an Important Turning Point in Its Growth
New seasonal blog offers parents practical ways to plan family fun before October 31
$CYCU Boasts a 30 Million Annual Run Rate After Signing Largest Contract Ever, Valued Over $54 Million
Eagle Springs has restarted with a 5,000-barrel-per-day capacity, a proposed $50 million non-dilutive Nevada oil initiative and a substantial Utah resource opportunity, Sky Quarry $SKYQ is advancing its vision of a more integrated Western U.S. energy plat
Self-paced online training helps learners strengthen their bookkeeping knowledge and gain confidence using QuickBooks Online.
With relationships spanning 600 telecommunications operators, a potential reach of 2.3 billion end users, and fresh momentum in mobile entertainment, IQSTEL is advancing its strategy to transform a substantial telecommunications platform into a higher-mar
Platform named "Leading AI Procurement & AP Automation Platform 2026" in SME News UK Finance Awards
NRXP Reports Three Successfully Manufactured Commercial Lots, Two-Year Stability Data, and Commercially Releasable Supply Pending FDA Approval — While an $11.18 Million DARPA Contract Expands the Company's Research Opportunities
October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential
From "Diagnose and Treat" to "Predict, Alert and Intervene"—POMDOCTOR $POM. New AI-Powered Predictive Healthcare Vision Takes Center Stage in October 12 Announcement.
New SmallCapVoice interview with $SKYQ puts the spotlight on a restarted Nevada refinery, 5,000-barrel-per-day potential, a non-dilutive $50 million oil-development initiative and Sky Quarry's plans to ramp both Nevada and Utah operations.
From AI-Powered Chronic Disease Management to "Hardware + AI + Payment," POMDOCTOR Is Building a Broader Digital Healthcare Infrastructure Platform
Today's landmark defense contract launches the FDA-approved SPARC-TMS trial while NRx simultaneously advances its preservative-free ketamine program, HOPE Therapeutics and an expanding CNS pipeline
MarketCapGear.com Brings Stock Market Culture & Fashion to the Streets w a Line of Financial Finesse
From $GME and $AMC to "Money Never Sleeps," the independent apparel brand is turning market culture, trading terminology and investor identity into wearable fashion.
Cycurion, Inc. (N A S D A Q: CYCU) Expands From Government Cybersecurity Into Public Safety, Healthcare, AI, Fleet Analytics and Commercial Markets as Q2 Margins Surge Nearly 5X and Management Authorizes $500K Share Repurchases
Today's air-permit approval and immediate Eagle Springs restart mark a major operational milestone, while 5,000-barrel-per-day capacity, 15,000 barrels of crude inventory, Nevada oil-development plans and a tightening Western refining market put Sky Quarr
Today's Proposed Combination Could Significantly Expand CDIX's Healthcare Footprint — While New Equity, Warrants and Exercise Activity Put the Capital Structure Squarely in Focus
With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts
Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to commercializ
NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026 commercializat